CCBs are a leading cause of poisoning mortality reported to poison centers. [1-2] Two pharmacological classes exist: dihydropyridines (amlodipine, nifedipine) causing primarily vasodilation, and nondihydropyridines (verapamil, diltiazem) with more pronounced cardiac effects including negative chronotropy and dromotropy. These distinctions are often lost in overdose, where patients present with severe shock from bradycardia, vasodilation, or loss of inotropy. [1-2] Amlodipine is now the most common CCB involved in poisoning and can cause profound vasodilation mediated by nitric oxide release. [1][3]
1. History
- Agent ingested: Identify specific CCB (dihydropyridine vs. nondihydropyridine), formulation (immediate-release vs. sustained-release), and dose
- Time of ingestion: Critical for decontamination decisions and anticipating delayed toxicity; sustained-release formulations can delay peak toxicity by several hours [4-5]
- Intentional vs. accidental: Suicidal intent, pediatric exploratory ingestion, or therapeutic error
- Co-ingestants: Ask specifically about beta-blockers, digoxin, acetaminophen, salicylates, and other cardiotoxic agents [6]
- Symptom progression: Dizziness, lightheadedness, syncope, nausea, altered mental status
- Access to medications: Pill count, pharmacy records
2. Alarm Features
- Hypotension refractory to IV fluids — hallmark of severe toxicity [2][6]
- Bradycardia (especially with nondihydropyridines); note that dihydropyridine overdose (e.g., amlodipine) may initially present with hypotension and reflex tachycardia before developing bradycardia [6]
- Altered mental status or obtundation — indicates end-organ hypoperfusion
- Rising lactate — marker of tissue hypoperfusion and severity [6]
- Hyperglycemia — serum glucose correlates directly with severity of CCB intoxication; peak glucose >300 mg/dL and percentage increase in glucose are better predictors of severity than hemodynamic parameters alone [7]
- Sustained-release formulation ingestion — anticipate delayed and prolonged toxicity [5]
- Cardiac arrest — can occur rapidly, especially with verapamil [1]
3. Medications
First-line treatments (per AHA 2025 Guidelines and expert consensus): [1][8]
- IV calcium: Calcium gluconate (preferred peripherally) or calcium chloride (central line); target ionized calcium up to twice normal for greater effect [1-2]
- Atropine: 0.5–1 mg IV for symptomatic bradycardia; treatment failures are common [2]
- High-dose insulin (HDI): Bolus 1 unit/kg IV, then infusion 0.5–1 unit/kg/hr; improves inotropy; co-administer dextrose (D10–D25) and monitor glucose/potassium closely [1][9-10]
- Vasopressors: Norepinephrine most commonly used (doses up to 100 mcg/min reported); no evidence to guide choice of vasopressor [1]
Second-line / refractory treatments
- Methylene blue: 1–2 mg/kg IV for refractory vasodilatory shock, especially amlodipine; responses are mixed and may be transient [1-2]
- Glucagon: 3–10 mg IV bolus then 3–5 mg/hr infusion; variable response, tachyphylaxis common, causes vomiting [2][9]
- VA-ECMO: For refractory cardiogenic shock; survival rates up to 77% reported; pH <7.1 associated with increased mortality [1-2]
- Electrical pacing: May be reasonable for hemodynamically significant bradydysrhythmias but not always effective, particularly with complete AV nodal blockade [2]
Medications to avoid or use cautiously
- Intralipid emulsion (ILE): Expert consensus advises against routine use; may increase GI absorption of lipophilic drugs and worsen poisoning; associated with abrupt cardiac arrest in some reports; role limited to peri-arrest/cardiac arrest as a last resort [1-2]
- HDI caution with amlodipine: HDI is a potent vasodilator and should be used cautiously in pure vasodilatory shock (amlodipine); best used when cardiogenic component is suspected [3]
4. Diet
- NPO in acute setting given risk of aspiration and potential need for intubation or procedural intervention
- Dextrose supplementation is critical during HDI therapy to maintain euglycemia [1][9]
- Not a primary management consideration in the acute toxicology setting
5. Review of Systems
- Cardiovascular: Chest pain, palpitations, syncope, presyncope
- Neurologic: Dizziness, confusion, lethargy, seizures (rare, more common with verapamil)
- GI: Nausea, vomiting (may indicate severity or co-ingestion)
- Respiratory: Dyspnea (pulmonary edema from cardiogenic shock or volume overload from resuscitation)
- Psychiatric: Suicidal ideation, intent, plan (if intentional ingestion)
6. Collateral History and Family History
- Collateral from EMS, family, or bystanders: Pill bottles at scene, suicide note, witnessed ingestion, time of discovery
- Pharmacy records: Confirm prescribed CCB, dose, quantity dispensed, refill dates
- Psychiatric history: Prior suicide attempts, current stressors
- Family history: Less relevant in acute toxicology; however, family history of cardiac conduction disease may lower threshold for toxicity
7. Risk Factors
- Intentional self-harm — accounts for most severe cases
- Sustained-release formulations — delayed and prolonged toxicity [4-5]
- Co-ingestion with beta-blockers — synergistic cardiovascular depression [4]
- Elderly patients — reduced hepatic metabolism, increased sensitivity
- Hepatic impairment — CCBs are almost entirely hepatically eliminated; impaired clearance prolongs toxicity [5]
- Pediatric patients — even 1–2 tablets of verapamil or nifedipine can be lethal in toddlers
- Pre-existing cardiac conduction disease or heart failure
8. Differential Diagnosis
- Beta-blocker overdose: Very similar presentation (hypotension + bradycardia); key differentiator is hypoglycemia (beta-blocker) vs. hyperglycemia (CCB); propranolol causes QRS widening and seizures; sotalol causes QT prolongation [2][6-7]
- Digoxin toxicity: Bradycardia, AV block, hyperkalemia; check digoxin level
- Clonidine/central alpha-agonist overdose: Bradycardia, hypotension, miosis, CNS depression
- Organophosphate poisoning: Bradycardia with cholinergic toxidrome (SLUDGE)
- Acute MI / cardiogenic shock: ECG and troponin to differentiate
- Septic shock: Fever, infectious source, vasodilatory physiology
- High-grade AV block from other causes (structural, ischemic)
9. Past Medical History
- Current CCB prescription — therapeutic misadventure vs. intentional overdose
- Cardiac history: Pre-existing conduction disease, heart failure, cardiomyopathy
- Hepatic disease: Impaired CCB metabolism [5]
- Diabetes: Baseline glucose important for interpreting hyperglycemia and managing HDI
- Renal disease: Does not significantly affect CCB pharmacokinetics but impacts overall resuscitation [5]
- Prior overdose attempts
10. Physical Exam
- Vitals: Hypotension and bradycardia are the hallmark findings; dihydropyridine OD may show hypotension with initial tachycardia [6]
- Cardiovascular: Bradycardia, weak pulses, delayed capillary refill, JVD (if cardiogenic shock), cool extremities
- Neurologic: Altered mental status ranging from lethargy to coma; seizures rare
- Respiratory: Crackles (pulmonary edema), respiratory failure
- Skin: Pallor, diaphoresis, mottling (poor perfusion)
- GI: Ileus may develop (reduced gut motility)
11. Lab Studies
- Point-of-care glucose: Hyperglycemia is characteristic of CCB toxicity and correlates with severity; peak glucose >300 mg/dL and >71% increase from baseline predict severe toxicity [7]
- BMP/CMP: Electrolytes (monitor K⁺ closely during HDI — hypokalemia is common), renal function for end-organ assessment, calcium [1]
- Lactate: Elevated lactate indicates tissue hypoperfusion and severity [6]
- VBG/ABG: Assess for metabolic acidosis; pH <7.1 associated with poor outcomes on ECMO [1]
- Troponin: Rule out concurrent ACS
- Acetaminophen, salicylate, digoxin levels: Evaluate for co-ingestion [6]
- Ionized calcium: Monitor during calcium infusion therapy
- Serial glucose and potassium: Every 30–60 minutes during HDI therapy [1][11]
- CBC, coagulation studies, hepatic function: Baseline assessment
No specific drug level confirms CCB toxicity; diagnosis is clinical. [6]
12. Imaging
- Chest X-ray: Evaluate for pulmonary edema (cardiogenic shock, volume overload from resuscitation)
- Bedside echocardiography (POCUS): Critical for differentiating cardiogenic vs. vasodilatory shock — guides treatment selection (HDI for cardiogenic component, vasopressors for vasodilatory component) [3-4]
- Abdominal X-ray/KUB: May identify pill fragments, bezoar, or sustained-release tablets in GI tract; can guide decontamination decisions
- CT head: If altered mental status is disproportionate to hemodynamic status or if co-ingestion/trauma suspected
13. Special Tests
- Bedside echocardiography: Most important adjunct — assess LV function, cardiac output, and guide therapy [4]
- Invasive hemodynamic monitoring: Consider arterial line and central venous access for vasopressor titration
- Point-of-care ultrasound (IVC assessment): Guide fluid resuscitation
- Poison center consultation: Recommended for all significant CCB ingestions
- Toxicology consultation: For refractory cases and ECMO consideration
14. ECG
- Sinus bradycardia: Most common finding [5][12]
- AV conduction delays: First-degree AV block, second-degree (Mobitz I or II), third-degree (complete) heart block — especially with verapamil and diltiazem [5][12]
- Junctional or idioventricular escape rhythms: In severe cases
- QRS typically narrow (unlike sodium channel blocker toxicity) — helps differentiate from TCA or propranolol overdose
- QTc usually normal — helps differentiate from sotalol overdose
- ST changes: May occur secondary to hypoperfusion rather than primary ischemia
- Obtain serial ECGs: Monitor for progressive conduction delays
15. Assessment
CCB toxicity produces cardiovascular collapse through three mechanisms: negative inotropy, negative chronotropy, and vasodilation. [1-2] The relative contribution of each depends on the agent:
- Verapamil: Most potent cardiac depressant; highest mortality; prominent bradycardia and AV block [5]
- Diltiazem: Intermediate cardiac and vascular effects
- Amlodipine: Profound vasodilatory shock (nitric oxide–mediated), often with preserved or even increased heart rate initially; now the most common CCB in poisoning [1][3]
Severity stratification:
- Mild: Asymptomatic or mild hypotension responsive to fluids
- Moderate: Hypotension requiring vasopressors, symptomatic bradycardia
- Severe: Refractory shock, cardiac arrest, multi-organ failure
Complications: Non-cardiogenic pulmonary edema, mesenteric ischemia (from vasopressors or hypoperfusion), acute kidney injury, lactic acidosis, cardiac arrest. [1]
16. Treatment Plan
Immediate stabilization
- ABCs, IV access (ideally 2 large-bore + central line), continuous cardiac monitoring
- IV crystalloid bolus for hypotension
GI decontamination: [8][13-15]
- Activated charcoal (1 g/kg, max 50–100 g): Appropriate for CCB ingestion; the Clinical Toxicology Recommendations Collaborative supports administration up to 6 hours post-ingestion (and beyond if ongoing absorption is suspected, e.g., sustained-release formulations); an additional dose may be appropriate for verapamil specifically [14-15]
- Whole-bowel irrigation (PEG solution 1.5–2 L/hr in adults): Consider for sustained-release formulations, especially if presenting >2 hours post-ingestion; contraindicated if hemodynamically unstable or unprotected airway [13][15]
Stepwise pharmacotherapy (per AHA 2025 and expert consensus): [1][8]
First-line (initiate simultaneously based on clinical severity):
- Atropine 0.5–1 mg IV (may repeat) for symptomatic bradycardia
- IV calcium: Calcium gluconate 60 mL of 10% solution (or CaCl₂ 20 mL of 10% via central line) IV over 10–20 min; may repeat; target ionized Ca²⁺ up to 2× normal [1-2]
- High-dose insulin: 1 unit/kg IV bolus → 0.5–1 unit/kg/hr infusion; co-administer D10–D25 infusion; monitor glucose q30min and K⁺ q1hr [1][9]
- Norepinephrine or epinephrine infusion for persistent hypotension [1][8]
Refractory to first-line:
- Escalate HDI infusion rate (no established ceiling; doses up to 10 units/kg/hr reported) [1]
- Methylene blue 1–2 mg/kg IV for vasodilatory shock (especially amlodipine) [1]
- Glucagon 3–10 mg IV bolus → 3–5 mg/hr infusion [9][16]
- Transcutaneous/transvenous pacing for hemodynamically significant bradydysrhythmias [2][16]
Refractory shock / peri-arrest / cardiac arrest:
- VA-ECMO if available — survival rates up to 77% [1-2]
- ILE (20% lipid emulsion 1.5 mL/kg bolus → 0.25 mL/kg/min for 30–60 min): Only as last resort in cardiac arrest/peri-arrest; not recommended routinely [1-2]
The following figure from the 2018 ACC/AHA/HRS Bradycardia Guidelines illustrates the acute bradycardia management algorithm, including drug-specific antidote pathways:
17. Disposition
- ICU admission: All symptomatic patients and all patients with intentional overdose of sustained-release formulations require ICU-level monitoring with continuous telemetry [6]
- Observation (minimum 24 hours): Asymptomatic patients after ingestion of sustained-release CCBs or amlodipine, given potential for delayed toxicity [5][8]
- Observation (minimum 6–8 hours): Asymptomatic patients after immediate-release CCB ingestion; if no symptoms develop, may consider step-down
- Psychiatric evaluation: Mandatory before discharge for all intentional ingestions
- Specialist consultation triggers:
- Toxicology/Poison Center: All significant ingestions
- Cardiology: Refractory dysrhythmias, consideration of pacing
- Cardiac surgery/ECMO team: Refractory shock despite maximal medical therapy [1]
18. Follow Up / Return Precautions
- Return immediately for: Dizziness, lightheadedness, syncope, palpitations, chest pain, shortness of breath, confusion, or recurrent symptoms
- Expected recovery: Most patients who survive the acute phase recover fully; prolonged ICU stays may be needed for sustained-release formulations
- Follow-up timing: Cardiology follow-up within 1–2 weeks if any conduction abnormalities were noted; primary care within 1 week
- Medication reconciliation: Review all cardiac medications; ensure safe prescribing practices to prevent recurrence
- Psychiatric follow-up: Arrange outpatient mental health care for intentional ingestions before discharge
- Patient counseling: Educate on safe medication storage (especially with children in the home); even 1–2 tablets of certain CCBs can be fatal in toddlers
References
1. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.
2. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.
3. Developments in the Epidemiology of Calcium Channel Blocker Poisoning and Implications for Management. — Simpson MD, Cole JB. Current Opinion in Critical Care. 2024.
4. Calcium Channel Antagonist and Beta-Blocker Overdose: Antidotes and Adjunct Therapies. — Graudins A, Lee HM, Druda D. British Journal of Clinical Pharmacology. 2016.
5. Poisoning Due to Calcium Antagonists. Experience With Verapamil, Diltiazem and Nifedipine. — Pearigen PD, Benowitz NL. Drug Safety. 1991.
6. Pearls and Pitfalls for the Emergency Clinician: Beta Blocker and Calcium Channel Blocker Toxicity. — Suarez F, Koyfman A, Long B. The Journal of Emergency Medicine. 2026.
7. Assessment of Hyperglycemia After Calcium Channel Blocker Overdoses Involving Diltiazem or Verapamil. — Levine M, Boyer EW, Pozner CN, et al. Critical Care Medicine. 2007.
8. Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults. — St-Onge M, Anseeuw K, Cantrell FL, et al. Critical Care Medicine. 2017.
9. 2018 ACC/AHA/HRS Guideline on The evaluation and Management Of patients With Bradycardia and Cardiac conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Writing Committee Members, Kusumoto FM, Schoenfeld MH, et al. Heart Rhythm. 2019.
10. High-Dose Insulin Should Be Used Before Vasopressors/Inotropes in Calcium-Channel Blocker Toxicity. — Mégarbane B. British Journal of Clinical Pharmacology. 2023.
11. Evaluation of High-Dose Insulin/Euglycemia Therapy for Suspected Β-Blocker or Calcium Channel Blocker Overdose Following Guideline Implementation. — Schult RF, Nacca N, Grannell TL, Jorgensen RM, Acquisto NM. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 2022.
12. Calcium-Antagonist Drugs. — Abernethy DR, Schwartz JB. The New England Journal of Medicine. 1999.
13. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
14. Recommendations From the Clinical Toxicology Recommendations Collaborative on the Administration of Activated Charcoal in Acute Oral Overdose. — Hoegberg LCG, Gosselin S, Buckley NA, et al. Clinical Toxicology. 2026.
15. Gut Decontamination in the Poisoned Patient. — Gosselin S, Hoegberg LCG, Hoffman RS. British Journal of Clinical Pharmacology. 2025.
16. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. — Tisdale JE, Chung MK, Campbell KB, et al. Circulation. 2020.
17. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.